Bookmark and Share

Ashraf Z. Badros

Ashraf Z. Badros M.B.,Ch.B.

Academic Title: Professor
Primary Appointment: Medicine
Administrative Title: Director Of The Multiple Myeloma Serivce
Location: UMMC, Room N9E12
Phone: (410) 328-1230
Fax: (410) 328-1975

Research Interests:

My clinical research is focused on the treatment of multiple myeloma. We have evaluated many immunological approaches to eradicate residual myeloma cells especially in the high-risk setting following autologous stem cell transplantation using natural killer (NK) and interleukin -2 (IL-2) activated cells. We have implanted non-myeloablative allogeneic grafts in myeloma confirming the promising effects of graft versus myeloma effects (GVM). The long-term follow up of these patients have been disappointing with few if any cures. Thus I moved my focus to development of targeted novel therapeutics. We have completed a gene therapy trial using G-3039 “Bcl-antisense” that showed activity in relapsed myeloma patients through overcoming drug resistance and stimulation of a brisk immune response to the CpG motif of the anti-sense molecule. We have introduced the Proteosome inhibitor “bortezomib” in the newly diagnosed myeloma patients; these studies evaluated the effect of bortezomib on the disease as well as on stem cell collection.  Currently, we are evaluating various combinations of novel therapies in MM such as Lenalidomide and histone deacetylase inhibitors (SAHA) in relapsed myeloma patients alone and in combinations with dexamethasone and/or bortezomib.


Recently and in collaboration with our colleagues in the dental department we characterized a clinical syndrome called osteonecrosis of the jaw as a new complication affecting myeloma patients who have been on long-term bisphosphonates therapy. We are currently studying the effects of these drugs on other bones and collaborating with other institution in an attempt to understand the pathogenesis of this new clinical entity.


Meehan KR, Badros A, S Frankel, R Cahill, E Areman, M Jensen, R Sacher, A Mazumder.  A Pilot Study Evaluating IL-2 Activated Hematopoietic Stem Cell Transplantation for Hematological Malignancies. Transfusion Medicine 1997; 6:457- 464.

Lim SH, Badros A, Lue C and Barlogie B. Distinct T cell clonal expansion in the vicinity of tumor cells in plasmacytoma. Cancer 2001; 91: 900-908.

Butch AW, Badros A, Desikan KR, Munshi NC. Expression of a free gamma heavy chain in serum following autologous stem cell transplantation for IgG kappa multiple myeloma. Bone Marrow Transplantation 2001; 27: 663-666.

Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, Zangari M, Mehta J, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574-2579.

Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.

Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, Fassas A, Anaissie E, Munshi N, Tricot G. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. British Journal of Haematology. 2001; 114:600-607.

Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G. Results of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Failure. British Journal of Haematology 2001; 114: 822-829.

Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N, Barlogie B, Cottler-Fox M. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002; 42: 205-209.

Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G. Improved outcome of Non-myeloablative Allogeneic Transplantation in Multiple Myeloma. Journal of Clinical Oncology 2002; 20: 1295-1303.

Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. American Journal of Medicine 2002; 112: 412-413.

Badros A, Morris C, Zangari M, Barlogie B, Tricot G. Thalidomide Paradoxical Effect on Concomitant Multiple Myeloma and Myelodysplasia. Leukemia and Lymphoma 2002; 43: 1267-1271.

Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Experimental Hematology  2003; 31: 73-80

Bolanos-Meade J, Phillips GL 2nd, Badros A. Tandem transplantation in multiple myeloma. Oncology (Huntingt) 2003; 17: 389-98; discussion 398-400, 405-7.

Kasamon KM, Drachenberg CI, Rapoport AP, Badros A. Catastrophic Antiphospholipid Syndrome: Atypical Presentation in the Setting of Chronic Graft Versus Host Disease: Case Report and Review of the Literature. Haematologica 2005; 90: ECR 17.

Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients. Journal of Clinical Oncology 2005; 23: 4089-99. Epub 2005 May 2.

Badros A, Porter N, Zimrin A. Bevacizumab Therapy for POEMS Syndrome. Blood 2005; 106, 1135.
Badros A, Gahres N. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait. Clin Adv Hematol Oncol. 2005; 3: 916-7; discussion 918.

Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. Journal of Clinical Oncology 2006; 24: 945-52.

Bridges B, Donegan S, Badros A. Cidofovir Bladder Instillation for the Treatment of BK Hemorrhagic Cystitis after Allogeneic Stem Cell Transplantation. American Journal of Hematology. (In Press).